PMID- 23757385
OWN - NLM
STAT- MEDLINE
DCOM- 20140127
LR  - 20151119
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 47
IP  - 7-8
DP  - 2013 Jul-Aug
TI  - Drug interactions and the pharmacist: focus on everolimus.
PG  - 1055-63
LID - 10.1345/aph.1R769 [doi]
AB  - OBJECTIVE: To evaluate everolimus drug-drug and drug-food interactions, with an 
      emphasis on patients with cancer. DATA SOURCES: Literature was accessed through 
      PubMed (1990-March 2013) using Boolean combinations of the terms drug 
      interactions, herb-drug interactions, food-drug interactions, everolimus, 
      antineoplastic agents, hormonal, and breast neoplasms. In addition, reference 
      citations from publications and the prescribing information for everolimus were 
      reviewed. STUDY SELECTION AND DATA EXTRACTION: All articles published in English, 
      including human, animal, and in vitro studies, identified from the data sources 
      were included. DATA SYNTHESIS: Patients with cancer are at increased risk for 
      drug interactions because of the multiple medications they are prescribed to 
      treat their disease and comorbid conditions. Everolimus, an oral mammalian target 
      of rapamycin (mTOR) inhibitor, is indicated for the treatment in adults with 
      progressive neuroendocrine tumors of pancreatic origin that are unresectable, 
      locally advanced, or metastatic; adults with advanced renal cell carcinoma after 
      failure of treatment with sunitinib or sorafenib; and, recently, postmenopausal 
      women with advanced hormone receptor-positive, human epidermal growth factor 
      receptor 2-negative breast cancer in combination with exemestane after failure of 
      treatment with letrozole or anastrozole. As its use increases among patients with 
      cancer, clinicians must be knowledgeable about potential drug and/or 
      food/nutrient interactions and the mechanisms by which these interactions occur, 
      to mitigate and prevent unwanted reactions and ensure patient safety. 
      CONCLUSIONS: Everolimus is a widely used oral mTOR inhibitor that has the 
      potential for drug interactions that may affect therapeutic outcomes, produce 
      toxicities, or both. This article provides a review of evidence-based literature, 
      along with the prescribing information, to educate clinicians on the significance 
      of these drug interactions and their impact on management with everolimus.
FAU - Grabowsky, Jennifer A
AU  - Grabowsky JA
AD  - Early Phase Investigational Therapeutics, Helen Diller Family Comprehensive 
      Cancer Center, University of California, San Francisco, USA. 
      Jennifer.Grabowsky@ucsfmedctr.org
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130611
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/administration & dosage/*metabolism
MH  - Drug Interactions/*physiology
MH  - Everolimus
MH  - Food-Drug Interactions/*physiology
MH  - Herb-Drug Interactions/*physiology
MH  - Humans
MH  - *Pharmacists/standards
MH  - Sirolimus/administration & dosage/*analogs & derivatives/metabolism
EDAT- 2013/06/13 06:00
MHDA- 2014/01/28 06:00
CRDT- 2013/06/13 06:00
PHST- 2013/06/13 06:00 [entrez]
PHST- 2013/06/13 06:00 [pubmed]
PHST- 2014/01/28 06:00 [medline]
AID - aph.1R769 [pii]
AID - 10.1345/aph.1R769 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2013 Jul-Aug;47(7-8):1055-63. doi: 10.1345/aph.1R769. Epub 2013 
      Jun 11.